Brustdiagnostik – Mammografie, Sonografie und MRT – Wann und warum?

Prof. Dr. med. Alexander Mundinger und Prof. Dr. med. Helmut Madjar
Seiten 6-8

 

  1. Kassenärztliche Bundesvereinigung: Einführung eines bundesweiten Mammographie-Screening-Programms. Beilage zum Dt. Ärztebl 2004; 4A:1-44.
  2. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. European Communities. Printed in Belgium 2006; Link: europa.eu.int
  3. American College of Radiology. ACR Breast Imaging Reporting and Data System, Breast Imaging Atlas. Reston VA; American College of Radiology 2003.
  4. Evaluationsbericht: Ergebnisse des Mammographiescreeningprogramms in Deutschland. Kooperationsgemeinschaft Mammografie 2005-2007; Link: www.mammo-programm.de/cms_upload/datenpool/evaluationsbericht05-07_web.pdf
  5. Tabár L, Tony Chen HH, Amy Yen MF, Tot T, Tung TH, Chen LS, Chiu YH, Duffy SW, Smith RA. Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma. Cancer  2004 Oct 15;101(8):1745-59.
  6. Glasziou P, Houssami N. The evidence base for breast cancer screening. Prev Med. 2011 Sep 1;53(3):100-102.
  7. Tabár L, Vitak B, Chen TH, Yen AM, Cohen A, Tot T, Chiu SY, Chen SL, Fann JC, Rosell J, Fohlin H, Smith RA, Duffy SW. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 2011 Sep;260(3):658-663.
  8. Heywang-Köbrunner SH, Schreer I, Heindel W, Katalinic A. Imaging studies for the early detection of breast cancer. Dt. Arztebl Int. 2008 Aug;105(31-32):541-547.
  9. Mundinger A, Madjar H, Rodeck B. Ultraschall. in: Strahlenmedizin.  Ein Leitfaden für den Praktiker. Hrsg. Krukemeyer MG, Wagner W; Walter de Gruyter GmbH & Co. KG 2004
  10. Houssami N, Ciatto S. The evolving role of new imaging methods in breast screening. Prev Med. 2011 Sep 1;53(3):123-126.
  11. Sardanelli F, Di Leo G. Biostatistics for radiologists: Planning, performing, and writing a radiologic study. Springer Verlag Italia 2009;147-148.
  12. Skaane P, Skjennald A. Screen-film mammography versus full-field digital mammography with soft-copy reading: Randomized trial in a population-based screening program. The Oslo II Study. Radiology 2004 Jul;232(1):197-204.
  13. Juel IM, Skaane P, Hoff SR, Johannessen G, Hofvind S. Screen-film mammography versus full-field digital mammography in a population-based screening program. The Sogn and Fjordane study. Acta Radiol 2010 Nov;51(9):962-968.
  14. Sickles EA, Wolverton DE, Dee KE. Performance parameters for screening and diagnostic mammography: specialist and general radiologists. Radiology 2002;2224:861-869.
  15. Berg WA. Rationale for a trial of screening breast ultrasound: American College of Radiology Imaging Network (ACRIN) 6666. AJR Am J Roentgenol 2003 May;180(5):1225-1228.
  16. Nothacker M, Langer T, Weinbrenner S: Bildgebende Diagnostik in der Onkologie – Evidenzanalysen des Ärztlichen Zentrums für Qualität in der Medizin (ÄZQ) für S3-Leitlinien Z. Evid. Fortbild. Qual. Gesundheitswesen (ZEFQ) 2010;104:554–562.
  17. Leconte I, Feger C, Galant C, Berliere M, Berg BV, D'Hoore W, Maldague B. Mammography and subsequent whole breast sonography of nonpalpable breast cancers. The importance of radiologic breast density. AJR Am J Roentgenol. 2003 Jun;180(6):1675-1679.
  18. Berg WA. Supplemental screening sonography in dense breasts. Radiol Clin North Am. 2004 Sep;42(5):845-845.
  19. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27.825 patient evaluations, Radiology 2002 Oct;225(1):165-175.
  20. Barlow WE, Lehman CD, Zheng Y, Ballard-Barbash R, Yankaskas BC, Cutter GR, Carney PA, Geller BM, Rosenberg R, Kerlikowske K, Weaver DL, Taplin SH. Performance of diagnostic mammography for women with signs or symptoms of breast cancer. J Natl Cancer Inst. 2002 Aug 7;94:1151-1159.
  21. Schulz KS, Albert US. S3-Leitlinie zur Brustkrebs-Früherkennung in Deutschland. Frauenarzt 2002;43(6):657-662.
  22. Duda V F, Schreer I. Schulz-Wendtland R, Heywang-Köbrunner S, Schulz KD. Mammasonografie: Additives - Bildgebendes Verfahren in der Brustkrebsfrüherkennung. MANUAL II zur Stufe-3-Leitlinien Konsensuskonferenz. www.senologie.org oder in: Stufe-3-Leitlinie. Brustkrebsfrüherkennung in Deutschland.  Hrsg. Schulz KD,  Albert US; Zuckschwerdt Verlag 2004
  23. Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Böhm-Vélez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K. ACRIN 6666 Investigators. Combined screening with ultrasound and mammography versus mammography alone in women at elevated risk of breast cancer. JAMA 2008 May 14;299(18):2151-2163.
  24. Corsetti V, Houssami N, Ghirardi M, Ferrari A, Speziani M, Bellarosa S, Remida G, Gasparotti C,  Galligioni E,  Ciatto S. Evidence of the effect of adjunct ultrasound screening in women with mammography-negative dense breasts: Interval breast cancers at one year follow-up. Eur J Cancer. 2011;47(7):1021-1026.
  25. Oberaigner W, Daniaux M, Geiger-Gritsch S, Knapp R, Siebert U, Buchberger W. Introduction of organised mammography screening in Tyrol: Results following first year of complete rollout. BMC Public Health 2011;30(11):673-670.
  26. Einigung beim Brustkrebs-Screening. Besser als EU-Standards. MMA Medical Tribune. 2011;26(43), Link: www.medical-tribune.at/dynasite.cfm
  27. Boyer B, Hauret L, Bellaiche R, Gräf C, Bourcier B, Fichet G. Retrospectively detectable carcinomas: Review of the literature. J Radiol 2004;85:2071-2078.
  28. Hofvind S, Geller B, Skaane P. Mammographic features and histopathological findings of interval breast cancers. Acta Radiol 2008;49(9):975-981.
  29. Mundinger A, Wilson ARM, Weismann C et al. Breast ultrasound update. EJC Supplements. 2010;8:11-14.
  30. Moon HJ, Kim MJ, Kwak JY et al. Malignant lesions initially categorized as probably benign breast lesions: Retrospective review of ultrasonographic, clinical and pathologic characteristics. Ultrasound Med Biol 2010;36:551-559.
  31. Madjar H. Kursbuch Mammasonographie. Ein Lehratlas nach den Richtlinien der DEGUM und der KBV; Thieme Stuttgart New York 1999.
  32. Mendelson EB, Baum JK, Berg WA, Merritt CRB, Rubin E. Breast Imaging Reporting  and Data System, BI-RADS: Ultrasound, 1st Ed. Reston; American College of Radiology 2003.
  33. Madjar H, Rickard M, Jellins J, Otto R. IBUS guidelines for the ultrasonic examination of the breast. European J Ultrasound 1999;9:99-102.
  34. Madjar H, Ohlinger R, Mundinger A et al. BI-RADS-analogue DEGUM criteria for findings in breast ultrasound - consensus of the DEGUM Committee on Breast Ultrasound. Ultraschall Med 2006;27(4):374-379.
  35. Mundinger A, Wilson ARM, Weismann C,  Rizzatto G, Mendelson  EB, Madjar H, Durante E. Where do we stand in advanced breast ultrasound? EJC Supplements 2012; in press.
  36. Mundinger A, Diekmann F, Viehweg P. Ultraschall und US-BI-RADS. Fortschritte Röntgenstr. 2004;176:S41-S401.
  37. Moon WK, Noh DY, Im JG. Multifocal, Multicentric, and Contralateral Breast Cancers: Bilateral Whole-Breast US in the Preoperative Evaluation of Patients. Radiology 2002;224(2):569-576.
  38. Weismann C, Mayr C, Egger H, Auer A. Breast sonography -2D,3D, 4D ultrasound or Elastography? Breast Care 2011;6:98-103.
  39. Berg WA, Cosgrove DO, Doré CJ, Schäfer FKW, Svensson WE, Hooley RJ, Ohlinger R, Mendelson EB, Balu-Maestro C, Locatelli M, Tourasse C, Cavanaugh BC, Juhan V, Stavros AT, Tardivon A, Gay J, Henry JP, Cohen-Bacrie C, for the BE1 Investigators. Shear-wave elastography improves the specificity of breast US: The multinational study of 939 masses. Radiology 2012;262:435-449.
  40. Wojcinski S, Farrokh A, Weber S et al. Multicenter study of ultrasound real-time tissue elastography in 779 cases for the assessment of breast lesions: Improved diagnostic performance by combining the BI-RADS®-US classification system with sonoelastography. Ultraschall Med 2010;31:484-491.
  41. Chang JM, Moon WK, Cho N et al. Clinical application of shear wave elastography (SWE) in the diagnosis of benign and malignant breast diseases. Breast Cancer Res Treat. 2011:129:89-97.
  42. Lander MR, Tabár L. Automated 3-d breast ultrasound as a promising adjunctive screening tool for examining dense breast tissue. Semin Roentgenol 2011;46:302-308.
  43. Mundinger A. Ultrasound of the breast including interventions: An update. In: Hodler J, von Schulthess GK, Zollikofer CH L. Diseases of the heart, chest and breast 2011-2014. Springer Italy; 2011:259-266.
  44. Madjar H, Sauerbrei W, Hansen L. Multivariate analysis of flow data in breast lesions and validation in a normal clinical setting. Ultraschall Med 2011;32:511-517.
  45. Svensson WE, Pandian AJ, Hashimoto H. The use of breast ultrasound color Doppler vascular pattern morphology improves diagnostic sensitivity with minimal change in specificity. Ultraschall Med 2010;31:466-474.
  46. Krouskop TA, Wheeler TM, Kallel F et al. Elastic moduli of breast and prostate tissues under compression. Ultrasonic imaging 1998;20:260-274.
  47. Itoh A, Ueno E, Tohno E et al. Breast disease: clinical application of US elastography for diagnosis. Radiology 2006;239:341–350.
  48. Farrokh A, Wojcinski S, Degenhardt F. Diagnostic value of strain ratio measurement in the differentiation of malignant and benign breast lesions. Ultraschall in Med 2011;32:400-405.
  49. Heywang SH, Hahn D, Schmidt H, Krischke I, Eiermann W, Bassermann R, Lissner J. MR imaging of the breast using Gd-DTPA. J Comp Ass Tomogr 1986;10:199–204.
  50. Liberman L, Morris EA, Lee MJ, Kaplan JB, LaTrenta LR, Menell JH, Abramson AF, Dashnaw SM, Ballon DJ, Dershaw DD. Breast lesions detected on MR imaging: Features and positive predictive value. AJR Am J Roentgenol. 2002;179(1):171-178.
  51. Berg WA, Gutierrez L, NessAiver MS, Carter WB, Bhargavan M, Lewis RS, Ioffe OB. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233(3):830-849.
  52. Fischer U, Zachariae O, Baum F, von Heyden D, Funke M, Liersch T. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol 2004;14(10):1725-1731.
  53. Saslow D, Boetes C, Burke W et al.: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammo- graphy. CA Cancer J Clin 2007;57:75–89.
  54. Lehman CD, Isaacs C, Schnall MD et al. Cancer yield of mammography, MR, and US in high-risk women: Prospective multi-institu- tion breast cancer screening study. Radiology 2007;244:381–388.
  55. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23(33):8469–8476.
  56. Kuhl CK, Schrading S, Bieling HB, et al. MRI for diagnosis of pure ductal carcinoma in situ: A prospective observational study. Lancet 2007;370:485–92.
  57. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: Using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008;148:671–679.
  58. Houssami N, Ciatto S, Macaskill P et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: Systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;26:3248–3258.
  59. Hrung JM, Sonnad SS, Schwartz JS, Langlotz CP. Accuracy of MR imaging in the work-up of suspicious breast lesions: a diagnostic meta-analysis. Acad Radiol. 1999;6:387-397.
  60. Peters NH, Borel Rinkes IH, Zuithoff NP, Mali WP, Moons KG, Peeters PH. Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology 2008;246:116-124.
  61. Kuhl CK. Current status of breast MR imaging. Part 2. Clinical applications. Radiology 2007;244(3):672-691.
  62. Mann RM, Kuhl CK, Kinkel K, Boetes C. Breast MRI: Guidelines from the European Society of Breast Imaging. Eur Radiol 2008;18:1307–1318.
  63. Hambly NM, Liberman L, Dershaw DD, Brennan S, Morris EA. Background parenchymal enhancement on baseline screening breast MRI: Impact on biopsy rate and short-interval follow-up. AJR Am J Roentgenol 2011;196(1):218-224.
  64. King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA. Background Parenchymal Enhancement at Breast MR Imaging and Breast Cancer Risk. Radiology 2011; Apr14 (epub ahead of print)
  65. Baltzer P, Dietzel M, Vag T, Burmeister H, Gajda M, Camara O, Pfleiderer S, Kaiser W. Clinical MR Mammography: Impact of Hormonal Status on Background Enhancement and Diagnostic Accuracy. Fortschr Röntgenstr 2011;183:441-447.
  66. McCormack VA, Dos Santos Silva I: Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: A Meta-analysisCancer Epidemiol Biomarkers Prev 2006;15:1159-1169.
  67. Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, Böhm-Vélez M, Mahoney MC, Evans WP 3rd, Larsen LH, Morton MJ, Mendelson EB, Farria DM, Cormack JB, Marques HS, Adams A, Yeh NM, Gabrielli G; ACRIN 6666 Investigators. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 2012;307:1394-1404.
  68. Bruening W, Fontanarosa J, Tipton K, Treadwell JR, Launders J, Schoelles K. Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions. Ann Intern Med 2010 Feb 16;152(4):238-246.
  69. Parsian S, Rahbar H, Allison KH, Demartini WB, Olson ML, Lehman CD, Partridge SC. Nonmalignant breast lesions: ADCs of benign and high-risk subtypes assessed as false-positive at dynamic enhanced MR imaging. Radiology 2012;265:696-706.
  70. Baum F, Fischer U, Vosshenrich R, Grabbe E. Classification of hypervascularized lesions in CE MR imaging of the breast. Eur Radiol 2002;12(5):1087-1092.
  71. Müller-Schimpfle MP, Heindel W, Kettritz U, Schulz-Wendtland R, Bick U. Consensus Meeting of Course Directors in Breast Imaging, 7 May 2011, Frankfurt (Main), Topic: MRI of the breast. Röfo. 2012;184:919-924.
  72. Meeuwis C, Veltman J, van Hall HN, Mus RD, Boetes C, Barentsz JO, Mann RM. MR-guided breast biopsy at 3T: diagnostic yield of large core needle biopsy compared with vacuum-assisted biopsy. Eur Radiol 2012;22:341-349.
  73. Pinker K, Brader P, Karanikas G, El-Rabadi K, Bogner W, Gruber S, Reisegger M, Trattnig S, Helbich TH. Functional and molecular imaging of breast tumors. Radiologe 2010 Nov;50(11):1030-1038.
  74. Kumar R, Nadig MR, Chauhan A.Positron emission tomography: clinical applications in oncology. Part 1. Expert Rev Anticancer Ther 2005;5:1079-1094.
  75. Benard F, Turcotte E: Imaging breast cancer with single photon computed tomography and positron emission tomography. Breast Cancer Res 2005,7:153-162.
  76. Koolen BB, Aukema TS, González Martínez AJ, Vogel WV, Caballero Ontanaya L, Vrancken Peeters MJ, Vroonland CJ, Rutgers EJ, Benlloch Baviera JM, Valdés Olmos RA. First clinical experience with a dedicated PET for hanging breast molecular imaging. QJ Nucl Med Mol Imaging 2013;57:92-100.
  77. Berg WA, Madsen KS, Schilling K, Tartar M, Pisano ED, Larsen LH, Narayanan D, Kalinyak JE. Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer. AJR Am J Roentgenol 2012;198:219-232.
  78. Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast 2013 Feb 12. pii: S0960-9776(13)00002-7; doi: 10.1016/j.breast.2012.12.020.
  79. Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP. American Society of Clinical Oncology. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. Clin Oncol 2005;23:7703-7720.
  80. Kühn T, Bembenek A, Büchels H,  Decker T, Dunst J,  Müllerleile U, Munz DL, Ostertag H, Sautter-Bihl ML, Schirrmeister H, Tulusan AH, Untch M, Winzer KJ, Wittekind C. Wächterlymphknotenbiopsie beim Mammakarzinom: Interdisziplinärer Konsensus der Deutschen Gesellschaft für Senologie für eine qualitätsgesicherte Anwendung in der klinischen Routine. Nuklearmedizin 2004;43:4–9.
  81. Pesek S, Ashikaga T, Krag LE, Krag D. The false-negative rate of sentinel node biopsy in patients with breast cancer: A meta-analysis. World J Surg 2012;36:2239-2251.
  82. Moon WK, Noh DY, Im JG. Multifocal, Multicentric, and Contralateral Breast Cancers: Bilateral Whole-Breast US in the Preoperative Evaluation of Patients. Radiology 2002 Aug;224(2):569-576.
  83. Mundinger A. Ultrasound of the breast including interventions: an update. In Hodler J, von Schulthess GK, Zollikofer  CH L, editors. Diseases of the heart, chest and breast 2011-2014. Springer Italy 2011;259-266.
  84. Schulz-Wendtland R, Bock K, Aichinger U, et al. Ultrasound examination of the breast with 7.5 MHz and 13 MHz-transducers: Scope for improving diagnostic accuracy in complementary breast diagnostics? Ultraschall Med 2005;26:209–215.
  85. Mundinger A, Wilson ARM, Weismann C et al. Breast ultrasound update. EJC Supplements 2010; 8:11-14.
  86. Houssami N, Hayes DF. Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer? CA Cancer J Clin. 2009;59:290-302.
  87. Mundinger A. Staging the breast and axilla. EJC Supplements 2006;4:35-37.
  88. Lehman CD, DeMartini W, Anderson BO et al. Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Canc Netw 2009; 7:193-201.
  89. Sardanelli F. Overview of the role of pre-operative breast MRI in the absence of evidence on patient outcomes. Breast 2010;19:3-6.
  90. Turnbull L, Brown S, Harvey I et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: A randomised controlled trial. Lancet 2010;375:563-571.
  91. Peters NH, van Esser S, van den Bosch MA et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: The MONET - randomised controlled trial. Eur J Cancer 2011;47:879-886.
  92. Morrow M, Waters J, Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet 2011;378:1804-1811.
  93. Kim CJ, Bland KI, Yeatman JY. Assessment and designation of breast cancer. In Blend KI, Copeland III EM, eds. The Breast. Saunders, St. Louis 2004; 425–443.
  94. Takei H, Kurosumi M, Yoshida T, Ninomiya J, Hagiwara Y, Kamimura M, Hayashi Y, Tozuka K, Suemasu K, Inoue K, Tabei T. Current trends of sentinel lymph node biopsy for breast cancer: A surgeon's perspective. Breast Cancer 2007;14:362-370.
  95. Sianesi M, Ceci G, Ghirarduzzi A, Del Rio P, Guazzi A, Pisanelli B, Martella E, Ardizzoni A, Di Blasio B, Arcuri MF. Ann Ital Chir 2009;80:315-318.
  96. Thomssen C, Scharl A, Harbeck N. AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update. Breast Care 2011;6:299-313.
  97. Houssami N, Ciatto S, Turner RM, Cody HS 3rd, Macaskill P. Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: Meta-analysis of its accuracy and utility in staging the axilla. Ann Surg 2011;254:243-251.
  98. Alvarez S, Añorbe E, Alcorta P, López F, Alonso I, Cortés J. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: A systematic review. AJR Am J Roentgenol 2006 May;186(5):1342-1348.
  99. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark N. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010 Oct;11(10):927-33.
  100. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA 2011;305:569-575.
  101. Kaufmann M, von Minckwitz G, Rody A. Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast 2005;14:576-581.
  102. Chen X, Moore MO, Lehman CD, Mankoff DA, Lawton TJ, Peacock S, Schubert EK, Livingston RB: Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol 2004;11:1115-1124.
  103. Wasser K, Sinn HP, Fink C, Klein SK, Junkermann H, Ludemann HP, Zuna I, Delorme S. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 2003 Jun;13(6):1213-1223.
  104. Beresford M, Padhani AR, Goh V, Makris A. Imaging breast cancer response during neoadjuvant systemic therapy. Expert Rev Anticancer Ther 2005 Oct;5(5):893-905.
  105. Schott AF, Roubidoux MA, Helvie MA, Hayes DF, Kleer CG, Newman LA, Pierce LJ, Griffith KA, Murray S, Hunt KA, Paramagul C, Baker LH. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005 Aug;92(3):231-238.
  106. Wu LM, Hu JN, Gu HY, Hua J, Chen J, Xu JR. Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer? Breast Cancer Res Treat 2012;135:17-28.
  107. Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, von Minckwitz G, Brennan ME, Ciatto S. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst 2013;105(5):321-333.
  108. Kreienberg r (Hrsg.). Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Leitlinienprogramm Onkologie, 3. Auflage 2012; Langversion 3.0, AWMF-Register-Nummer: 032- 045OL.
  109. Houssami N, Abraham LA, Miglioretti DL, Sickles EA, Kerlikowske K, Buist DS, Geller BM, Muss HB, Irwig L. Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA 2011;305:790-799.
  110. Mundinger A, Martini C, Madjar H, Laubenberger J, Gufler H, Langer M. Ultrasound and mammography follow-up of findings after breast saving operation and adjuvant irradiation. Ultraschall Med 1996;17:7-13.
  111. Krämer S, Schulz-Wendtland R, Hagedorn K, Bautz W, Lang N. Magnetic resonance imaging in the diagnosis of local recurrences in breast cancer. Anticancer Res 1998;18:2159-2161.
  112. Pan L, Han Y, Sun X, Liu J, Gang H. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: A meta-analysis. J Cancer Res Clin Oncol 2010;136:1007-1022.
  113. Robertson C, Arcot Ragupathy SK, Boachie C, Dixon JM, Fraser C, Hernández R, Heys S, Jack W, Kerr GR, Lawrence G, MacLennan G, Maxwell A, McGregor J, Mowatt G, Pinder S, Ternent L, Thomas RE, Vale L, Wilson R, Zhu S, Gilbert FJ. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: Systematic reviews registry database analyses and economic evaluation. Health Technol Assess 2011 Sep;15.34:ISSN 1366-5278.
  114. Houssami N, Skaane P. Overview of the evidence on digital breast tomosynthesis in breast cancer detection. Breast 2013 Feb 16. pii: S0960-9776(13)00019-2; doi:10.1016/j.breast.2013.01.017.
  115. Mundinger A. New frontiers of advanced breast ultrasound. Insights Imaging 2013;4 (Suppl 1):S1-SS144 D:392.
  116. Mitchell G, Antill YC, Murray W, Kirk J, Salisbury E, Lindeman GJ, Di Iulio J, Milner AD, Devereaux L, Phillips KA Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation. Breast Cancer Res 2005;7:R1122-1131.

Das Rind als Modell für Fragestellungen der Reproduktionsmedizin und -biologie

Prof. Dr. med. vet. Christine Wrenzycki
Seiten 14-15

  1. Adams GP, Singh J, Baerwald AR. Large animal models for the study of ovarian follicular dynamics in woman. Theriogenology 2012;78: 1733-1748.
  2. Leidenfrost S, Boelhauve M, Reichenbach M,Güngör T, Reichenbach HD, Sinowatz F, Wolf E, Habermann FA. Cell arrest and cell death in mammalian preimplantation development: Lessons from the bovine model. PlosOne 2011; 6: e22121.
  3. Malhi PS, Adams GP, Mapletoft RJ, Singh J. Oocyte developmental competence in a bovine model of reproductive aging. Reproduction 2007;
    134: 233-239.
  4. Menezo V. Mouse and bovine models for human IVF. RMM Online 2002;
    4: 170-175.
  5. Wrenzycki C, Stinshoff H. Maturation environment and impact on subsequent developmental competence of bovine oocytes. Reprod Domest Anim. 2013;48 Suppl 1:38-43.
  6. Wrenzycki C, Herrmann D, Niemann H. Messenger RNA in oocytes and embryos in relation to embryo viability. Theriogenology 2007; 68
    Supplement 1: S77-S83.
  7. Wrenzycki C. Analyse der Genexpressionsmuster zur Beurteilung der Embryonenqualität. Journal für Reproduktionsmedizin und Endokrinologie 2007; 5: 234-239.
  8. Yapura J, Mapletoft RJ, Pierson R, Singh J, Naile J, Giesy JP, Adams GP. A bovine model for examining the effects of an aromatase inhibitor on ovarian function in woman. Fert Steril 2011; 96: 434-438.

Primärtherapie bei Endometriose – Hormonal oder operativ?

Prof. Dr. med. Dipl. Psych. Matthias J. Wenderlein
Seiten 17-24

  1. Seracchioli R et al. Long-term cyclic and continuous oral contraceptive therapie and endometrioma recurrence: A randomized controlled trial. Fertil Steril 2010(1);93:52-56.
  2. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM,Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT,CramerDW, Terry KL, VitonisAF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A; Ovarian Cancer Association Consortium. Association between endometriosis and risk of histological subtypes of ovarian cancer: A pooled analysis of case-control studies. Lancet Oncol 2012 Apr;13(4):385-394.
  3. Schömig A et al. Ameta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. JACC 2008;52:894-904.
  4. Hill-Kayser CE et al. Cosmetic outcomes and complications reported by patients having undergone breast-conserving treatment. Int J Radiat Oncol Biol Phys 2012 Jul 1;83(3):839-44.
  5. Guidice LC. Clinical practice endometriosis. N Engl J Med 2010;362: 2389-2398.
  6. Hudelist G et al. Diagnostic delay for endometriosisin Austria and Germany. Causes and possible consequences. Hum Reprod 2012; 27(12): 3412-3416.
  7. Wildman RP et al. Do changes in sex steroid hormones preced or follow increases in body weight during the menopause transition? Results from the study of women´s health across the nation. J Clin Endocrinol Metab 2012; 97: e1695-e1704.
  8. Wenderlein JM. Ein Drittel weniger Brustkrebsdiagnosen unter HRT. Frauenarzt 2011;11:1120-1121.

Gynäkologische Aspekte bei der Betreuung von Mädchen und jungen Frauen

PD Dr. med. Patricia G. Oppelt und Prof. Dr. med. Helmuth G. Dörr
Seiten 27-32

  1. Doswell BH, Visootsak J, Brady AN, Graham JM Jr. Turner syndrome: an update and review for the primary pediatrician. ClinPediatr (Phila) 2006; 45:301-13.
  2. Ranke MB, Saenger P. Turner's syndrome. Lancet 2001; 358:309-14.
  3. Dörr HG, Ranke MB. Therapie mit Wachstumshormon bei Ullrich-Turner-Syndrom. Aktuelle Empfehlungen eines Expertenworkshops. Monatsschrift für Kinderheilkunde 2010; 158:63-70.
  4. Gravholt CH. Epidemiological, endocrine and metabolic features in Turner syndrome. EurJ Endocrinol 2004; 151:657-87.
  5. Gravholt CH. Clinical practice in Turner syndrome. Nat Clin Pract Endocrinol Metab 2005; 1:41-52.
  6. Ranke MB, Dorr HG. Ersatztherapie mit Sexualsteroiden in der Adoleszenz bei Hypogonadismus. Konsensus eines Expertenworkshops. Monatsschr Kinderheilkd 2009; 157:260-6.
  7. Bryman I, Sylven L, Berntorp K, Innala E, Bergstrom I, Hanson C et al. Pregnancy rate and outcome in Swedish women with Turner syndrome. Fertil Steril 2011; 95:2507-10.
  8. Gravholt CH, Fedder J, Naeraa RW, Muller J. Occurrence of gonadoblastoma in females with Turner syndrome and Y chromosome material: a population study. J Clin Endocrinol Metab. 2000; 85:3199-3202.
  9. Brant WO, Rajimwale A, Lovell MA, Travers SH, Furness PD, 3rd, Sorensen M et al. Gonadoblastoma and Turner syndrome. J Urol 2006;175:1858-1860.
  10. Schulze C, Heusinger K, Dörr HG, Faschingbauer F, Beckmann M, Oppelt PG. Das Ullrich-Turner-Syndrom aus  gynäkologischer und geburtshilflicher Sicht. Frauenheilkunde up2date 2013;7:16.
  11. Wunsch L, Holterhus PM, Wessel L, Hiort O. Patients with disorders of sex development (DSD) at risk of gonadal tumour development: management based on laparoscopic biopsy and molecular diagnosis. BJU international 2012;110:E958-65.
  12. Donaldson MD, Gault EJ, Tan KW, Dunger DB. Optimising management in Turner syndrome: from infancy to adult transfer. ArchDisChild. 2006;
    91:513-20.
  13. Bondy CA. Care of girls and women with turner syndrome: a guideline of the turner syndrome study group. J Clin Endocrinol Metab 2007; 92:10-25.

Das Archimetraprinzip (Teil 3) – Endometriose und Adenomyose & Infertilität

Prof. Dr. med. Gerhard Leyendecker und Prof. Dr. med. Ludwig Wildt
Seiten 33-35

  1. Rokitanski von K. Über Uterusdrüsen-Neubildung. Z. Gesellschaft Ärzte
    (Wien) 1860;16:577-581.
  2. Emge LA. The elusive adenomyosis of the uterus. Its historical past and ist present state of recognition. Am J Obstet Gynecol 1962;83:1541-1563.
  3. Recklinghausen von F. Die Adenomyomata und Cystadenomyomata des Uterus und der Tubenwandung: ihre Abkunft von Resten des Wolff‘schen Körpers. August Hirschwald Verlag; Berlin 1896.
  4. Batt RE. A histoty of endometriosis; Springer New York 2011.
  5. Kossmann R. Die Abstammung der Drüseneinschlüsse in den Adenomyomen des Uterus und der Tuben. Arch. Gynäk 1897; 54:359-381.
  6. Pick L. Ein neuer Typus des voluminösen paraoöphoralen Adenomyoms. Arch. Gynäk. 1897;54:119.
  7. Cullen TS. Adenomyoma uteri diffusum benignum. Johns Hopkins Hosp. Rep 1896;6:133-157.
  8. Cullen TS. The distribution of adenomyoma containing uterine mucosa. Arch Surgery 1920;1:215-283.
  9. Meyer R. Über den Stand der Frage der Adenomyositis und Adenomyome im Allgemeinen und insbesondere über Adenomyositis seroepithelialis und Adenomyometritis sarcomatosa. 1919;43:745-750.
  10. Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 1927;14:422-469.
  11. Leyendecker G, Wildt L. A new concept of endometriosis and adenomyosis: tissue injury and repair. Horm Mol Biol Clin Invest 2011;5(2):125-142.
  12. Greene R, Stratton P, Cleary SD, Ballweg ML, Sinaii N. Diagnostic experience among 4.334 women reporting surgically diagnosed endometriosis. Fertil Steril 2009;91:32-39.
  13. Ridley JH. The histogenesis of endometriosis. Obste Gynec Surv 1968;23:1-35.
  14. Philipp E, Huber H. Die Entstehung der Endometriose. Gleichzeitig ein Beitrag zur Pathologie des interstitiellen Tubenabschnittes. Zbl Gynäkol 1939;63:7-39.
  15. Leyendecker G, Wildt L, Mall G. The pathophysiology of endometriosis and adenomyosis. Tissue injury and repair. Arch. Gynecol Obstet 2009;280:529-538.
  16. Leyendecker G, Wildt L. Die Pathophysiologie von Endometriose und Adenomyose. Morphologische, funktionelle und molekularbiologische Grundlagen. In: Kreienberg R, Ludwig H (eds): 125 Jahre Deutsche Gesellschaft für Gynäkologie und Geburtshilfe. Werte, Wissen, Wandel. Springer Heidelberg 2010;203-226.
  17. Leyendecker G, Kunz G, Noe M, Herbertz M and Mall G. Endometriosis: A dysfunction and disease of the archimetra. Hum Reprod Update 1998;4:752-762.
  18. Werth R, Grusdew W. Untersuchungen über die Entwicklung und Morphologie der menschlichen Uterusmuskulatur. Arch. Gynäkol 1898;55:325-409.
  19. Wetzstein R. Der Uterusmuskel: Morphologie. Arch. Gynecol 1965;202:1-13.
  20. Noe M, Kunz G, Herbertz M, Mall G and Leyendecker G. The cyclic pattern of the immunocytochemical expression of oestrogen and progesterone receptors in human myometrial and endometrial layers: Characterisation of the endometrial-subendometrial unit. Hum Reprod 1999; 14:101-110.
  21. De Vries K, Lyons EA, Ballard G, Levi CS, Lindsay DJ. Contractions of the inner third of the myometrium. Am J Obstet Gynaecol 1990;162:679-682.
  22. Lyons EA, Taylor PJ, Zheng, XH, Ballard G, Levi CS, Kredentser JV. Characterisation of subendometrial myometrial contractions throughout the menstrual cycle in normal fertile women. Fertil Steril 1991;55:771-775.
  23. Williams M, Hill, CJ, Scudamore I, Dunphy B, Cooke ID, Barratt CLR. Sperm numbers and distribution within the human fallopian tube around ovulation. Hum. Reprod 1993;8:2019-2026.
  24. Kunz G, Beil D, Deininger H, Wildt L, Leyendecker G The dynamics of rapid sperm transport through the female genital tract. Evidence from vaginal sonography of uterine peristalsis (VSUP) and hysterosalpingo-scintigraphy (HSSG). Hum. Reprod 1996;11:627-632.
  25. Wildt L, Kissler S, Licht P, Becker W. Sperm transport in the human female genital tract and its modulation by oxytocin as assessed by hysterosalpingography, hysterotonography, electrohysterography and Doppler sonography. Hum Reprod Update 1998;4:655-666.
  26. Schmiedehausen K, Kat S, Albert N, Platsch, G, Wildt, L. Kuwert T. Determination of velocity of tubar transport with dynamic hysterosalpingo-scintigraphy. Aug Nucl Med Commun 2003;24:865-870.
  27. Zervomanolakis I, Ott HW, Hadziomerovic D, Mattle V, Seeber BE, Virgolini I, Heute D, Kissler S, Leyendecker G, Wildt L. Physiology of upward transport in the human female genital tract. Ann N Y Acad Sci 2007;1101:1-20.
  28. Zervomanolakis I, Ott HW, Müller J, Seeber BE, Friess SC, Mattle V, Virgolini I, Heute D, Wildt L. Uterine mechanisms of ipsilateral directed spermatozoa transport: Evidence for a contribution of the utero-ovarian countercurrent system. Eur J Obstet Gynecol Reprod Biol 2009;144 Suppl 1:45-49.
  29. Garcia-Segura LM. Aromatase in the brain: not just for reproduction anymore. J Neuroendocrinol 2008;20:705-712.
  30. Leyendecker G, Herbertz M, Kunz G, Mall G. Endometriosis results from the dislocation of basal endometrium. Hum Reprod 2002;17:2725-2736.
  31. Leyendecker G. Endometriosis is an entity with extreme pleiomorphism. Hum Reprod 2000;15:4-7.
  32. Bird CC, Willis RA. The production of smooth muscle by the endometrial stroma of the adult human uterus. J Path Bact 1965;90:75-81.
  33. Fujii S, Konishi I, Mori T. Smooth muscle differentiation at endometrio-myometrial junction. An ultrastructural study. Virchows Archiv Anat Pathal Anat 1989;414:105-112.
  34. Leyendecker G, Kunz G, Wildt, L, Beil, D, Deiniger H. Uterine hyperperistalsis and dysperistalsis as dysfunctions of the mechanism of rapid sperm transport in patients with endometriosis and infertility. Hum Reprod 1996;11:1542-1551.
  35. Kunz G, Kissler S, Wildt L, Leyendecker G. Uterine peristalsis: directed sperm transport and fundal implantation of the blastocyst. In: Filicori M. (ed) Endocrine Basis of Reproductive Function. Monduzzi Bologna 2000;402-422.
  36. Leyendecker G, Kunz G, Kissler S, Leyendecker G. Adenomyosis and reproduction. Best Pract Res Clin Obstet Gynaecol 2006;20:523-546.
  37. Kunz G, Noe M, Herbertz M, Leyendecker G. Uterine peristalsis during the follicular phase of the menstrual cycle. Effects of oestrogen, antioestrogen and oxytocin. Hum Reprod Update 1998;4:647-654.
  38. Zingg HH, Rozen F, Chu K, Larcher A, Arslan A, Richard S, Lefèbvre D. Oxytocin and oxytocin receptor gene expression in the uterus. Recent Progr. Hormone Res 1995;50:255-273.
  39. Mitzumoto Y, Furuya K, Makimura N, Mitsui C, Seki K, Kimura T, Nagata I. Gene expression of oxytocin receptor in human eutopic endometrial tissues. Adv Exp Med Biol 1995;395:491-493.
  40. Leyendecker G, Kunz G, Herbertz M, Beil D, Huppert P, Mall G, Kissler S, Noe M, Wildt L. Uterine peristaltic activity and the development of endometriosis. Ann NY Acad Sci 2004;1034:338-355.
  41. Einer-Jensen N. Countercurrent transfer in the ovarian pedicle and its physiological implications. Oxford Rev Reprod Biol 1988;10:348-381.
  42. Kunz G, Herbertz M, Noe M, Leyendecker G. Sonographic evidence for the involvement of the utero-ovarian counter current system in the ovarian control of directed uterine sperm transport. Hum Reprod Update 1998;4:667-672.
  43. Kunz G, Beil D, Huppert P and Leyendecker G. Structural abnormalities of the uterine wall in women with endometriosis and infertility visualized by vaginal sonography and magnetic resonance imaging. Hum Reprod 2000;15:76-82.
  44. Kunz G, Beil D, Huppert P, Noe M, Kissler S, Leyendecker G. Adenomyosis in endometriosis - prevalence and impact on fertility. Evidence from magnetic resonance imaging. Hum Reprod 2005;20:2309-2316.
  45. Dueholm M, Lundorf E, Hansen ES, Sørensen JS, Ledertoug S, Olesen F. Magnetic resonance imaging and transvaginal ultrasonography for the diagnosis of adenomyosis. Fertil Steril 2001;76:588-594.
  46. Kunz G, Herbertz M, Beil D, Huppert P, Leyendecker G. Adenomyosis as a disorder of the early and late human reproductive period. Reprod Biomed Online. 2007;15:681-685
  47. Barrier BF, Malinowski MJ, Dick EJ Jr, Hubbard GB, Bates GW. Adenomyosis in the baboon is associated with primary infertility. Fertil Steril 2004;82 Suppl 3:1091-1094.
  48. Mäkäräinen L. Uterine contractions in endometriosis: effects of operative and danazol treatment. Obstet Gynecol 1988;9:1344-1352.
  49. Salamanca A. and Beltran, E. Subendometrial contractility in menstrual phase visualised by transvaginal sonography in patients with endometriosis. Fertil Steril 1995;64:193–195.
  50. Bulletti C, De Ziegler D, Polli V, Del Ferro E, Palini S and Flamigni C. Characteristics of uterine contractility during menses in women with mild to moderate endometriosis. Fertil Steril 2002;77:156-161.
  51. Kissler S, Hamscho N, Zangos S, Wiegratz I, Schlichter S, Menzel C, Doebert N, Gruenwald F, Vogl TJ, Gaetje R, Rody A, Siebzehnruebl E, Kunz G, Leyendecker G, Kaufmann M. Uterotubal transport disorder in adenomyosis and endometriosis - a cause for infertility. BJOG 2006;113:902-908.
  52. Kissler S, Zangos S, Wiegratz I, Kohl J, Rody A, Gaetje R, Doebert N, Wildt L, Kunz G, Leyendecker G, Kaufmann M. Utero-tubal sperm transport and its impairment in endometriosis and adenomyosis. Ann N Y Acad Sci 2007;1101:38-48.
  53. Takahashi K, Nagata H and Kitao M. Clinical usefulness of determination of estradiol levels in the menstrual blood for patients with endometriosis. Acta Obstet Gynecol Jpn 1989;41:1849-1850.
  54. Aghajanova L, Hamilton A, Kwintkiewicz J, Vo KC, Giudice LC. Steroidogenic enzyme and key decidualization marker dysregulation in endometrial stromal cells from women with versus without endometriosis. Biol Reprod 2009;80:105-114.
  55. Bulun SE. Endometriosis. N Engl J Med 2009;360:268-279.
  56. Yamamoto T, Noguchi T, Tamura T, Kitiwaki J, Okada H Evidence for oestrogen synthesis in adenomyotic tissues. Am. J. Obstet. Gynecol 1993;169:734-738.
  57. Noble LS, Simpson ER, Johns A, Bulun SE. Aromatas expression in endometriosis. J Clin Endocrinol Metab 1996;81:174-179.
  58. Noble LS, Takayama K, Zeitoun KM, Putman JM, Johns DA, Hinshelwood MM, Agarwal VR, Zhao Y, Carr BR, Bulun SE. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab 1997;82:600-606.
  59. Kitawaki J, Noguchi T, Amatsu T, Maeda K, Tsukamoto K, Yamamoto T, Fushiki S, Osawa Y, Honjo H. Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biol Reprod 1997;57:514-519.
  60. Hudelist G, Czerwenka K, Keckstein J, Haas C, Fink-Retter A, Gschwantler-Kaulich D, Kubista E, Singer CF. Expression of aromatase and estrogen sulfotransferase in eutopic and ectopic endometrium: Evidence for unbalanced estradiol production in endometriosis. Reprod Sci 2007;14:798-805.
  61. Absenger Y, Hess-Stumpp H, Kreft B, Kratzschmar J, Haendler B, Schutze N, Regidor PA, Winterhager E. Cyr61: A deregulated gene in endometriosis. Mol Hum Reprod 2004;10:399-407.
  62. Gashaw I, Hastings JM, Jackson KS, Winterhager E, Fazleabas AT. Induced endometriosis in the baboon (Papio anubis) increases the expression of the proangiogenic factor CYR61 (CCN1) in eutopic and ectopic endometria. Biol Reprod 2006;74:1060-1066.
  63. D'Hooghe TM, Bambra CS, Raeymaekers BM, De Jonge I, Lauweryns JM, Koninckx PR. Intrapelvic injection of menstrual endometrium causes endometriosis in baboons (Papio cynocephalus and Papio anubis). Am J Obstet Gynecol 1995;173:125-134.
  64. Fazleabas AT, Brudney A, Chai D, Langoi D, Bulun SE. Steroid receptor and aromatase expression in baboon endometriotic lesions. Fertil Steril 2003;80 Suppl 2:820-827.
  65. Nyachieo A, Chai DC, Deprest J, Mwenda JM, D'Hooghe TM. The baboon as a research model for the study of endometrial biology, uterine receptivity and embryo implantation. Gynecol Obstet Invest. 2007;64:149-155.
  66. Ashcroft GS, Ashworth JJ. Potential role of estrogens in wound healing. Am J Clin Dermatol 2003;4:737-743.
  67. Gilliver SC, Ashworth JJ, Ashcroft GS. The hormonal regulation of cutaneous wound healing. Clin Dermatol 2007;25:56-62.
  68. Mowa CN, Hoch R, Montavon CL, Jesmin S, Hindman G, Hou G. Estrogen enhances wound healing in the penis of rats. Biomed Res 2008;29:267-270.
  69. Sierra A, Lavaque E, Perez-Martin M, Azcoitia I, Hales DB, Garcia-Segura LM. Steroidogenic acute regulatory protein in the rat brain: Cellular distribution, developmental regulation and overexpression after injury. Eur J Neuroscience 2003;18:1458-1467.
  70. Lavaque E, Sierra A, Azcoitia I, Garcia-Segura LM. Steroidogenic acute regulatory protein in the brain. Neuroscience 2006;138:741-747.
  71. Yang G, Im HJ, Wang JH. Repetitive mechanical stretching modulates IL-1beta induced COX-2, MMP-1 expression, and PGE2 production in human patellar tendon fibroblasts. Gene 2005;363:166-172.
  72. Jeffrey JE, Aspden RM. Cyclooxygenase inhibition lowers prostaglandin E2 release from articular cartilage and reduces apoptosis but not proteoglycan degradation following an impact load in vitro. Arthritis Res Ther 2007;9:R129.
  73. Shioyama R, Aoki Y, Ito H, Matsuta Y, Nagase K, Oyama N, Miwa Y, Akino H, Imamura Y, Yokoyama O. Long-lasting breaches in the bladder epithelium lead to storage dysfunction with increase in bladder PGE2 levels in the rat. Am J Physiol Regul Integr Comp Physiol 2008;295:R714-718.
  74. Hadjiargyrou M, Ahrens W, Rubin CT. Temporal expression of the chondrogenic and angiogenic growth factor CYR61 during fracture repair. J Bone Miner Res 2000;15:1014-1023.
  75. Garcia-Segura LM, Wozniak A, Azcoitia I, Rodriguez JR, Hutchison RE, Hutchison AB. Aromatase expression by astrocytes after brain injury: Implications for local estrogen formation in brain repair. Neuroscience 1999;89:567-578.
  76. Gurates B, Bulun SE. Endometriosis: the ultimate hormonal disease. Semin Reprod Med. 2003;21:125-134.
  77. Kissler S, Schmidt M, Keller N, Wiegratz T, Tonn, T, Roth KW,Seifried E, Baumann R, Siebzehnruebl E, Leyendecker G, Kaufmann M. Real-time PCR analysis for estrogen receptor beta and progesterone receptor in menstrual blood samples – a new approach to a non-invasive diagnosis for endometriosis. Hum Reprod 2005; 20 (Suppl):i179(P496).
  78. Attar E, Bulun SE Aromatase and other steroidogenic genes in endometriosis: Translational aspects. Hum Reprod Update 2006;12:49-56.
  79. Attar E, Tokunaga H, Imir G, Yilmaz MB, Redwine D, Putman M, Gurates B, Attar R, Yaegashi N, Hales DB, Bulun SE. Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. J Clin Endocrinol Metab 2009;94:623-631.
  80. Harada M, Osuga Y, Hirota Y, Koga K, Morimoto C, Hirata T, Yoshino O, Tsutsumi O, Yano T, Taketani Y. Mechanical stretch stimulates interleukin-8 production in endometrial stromal cells: Possible implications in endometrium-related events. J Clin Endocrinol Metab 2005;90:1144-1148.
  81. Mahmood TA, Templeton A. Pathophysiology of mild endometriosis: review of literature. Hum Reprod 1990,5:765-784.
  82. Hadfield RM, Yudkin PL, Coe CL, Scheffler J, Uno H, Barlow DH, Kemnitz JW, Kennedy SH. Risk factors for endometriosis in the rhesus monkey (Macaca mulatta): A case-control study. Hum Reprod Update 1997;3:109-115.
  83. Moen MH, Muus KM. Endometriosis in pregnant and non-pregnant women at tubal sterilisation. Hum Reprod 1991;6:699-702.
  84. Mechsner S, Grum B, Gericke C, Loddenkemper C, Dudenhausen JW, Ebert AD. Possible roles of oxytocin receptor and vasopressin-1? receptor in the pathomechanism of dysperistalsis and dysmenorrhea in patients with adenomyosis uteri. Fertil Steril 2010;94:2541-2546.
  85. Bokor A, Debrock S, Drijkoningen M, Goossens W, Fülöp V, D'Hooghe T. Quantity and quality of retrograde menstruation: a case control study. Reprod Biol Endocrinol 2009;7:123-130.
  86. Maggi M, Magini A, Fiscella A, Giannini S, Fantoni G, Toffoletti F, Massi G, Serio M. Sex steroid modulation of neurohypophysial hormone receptors in human nonpregnant myometrium. J Clin Endocrinol Metab 1992;74:385-392.
  87. Bartosik D, Jakobs SL, Kelly LJ. Endometrial tissue in peritoneal fluid. Fertil Steril 1986;46:796-800.
  88. Marsh EE u. Laufer MR. Endometriosis in premenarcheal girls who do not have an obstructive anomaly. Fertil Steril 2005;83:758-760.
  89. Goji K. Twenty-four-hour concentration profiles of gonadotropin and estradiol (E2) in prepubertal and early pubertal girls: The diurnal rise of E2 is opposite the nocturnal rise of gonadotropin. J clin Endocrinol Metab 1993;77:1629-1635.
  90. Peters H. The human ovary in childhood and early maturity. Eur J Obstet Gynec Reprod Biol 1977;9:137-144.
  91. Leyendecker G, Wildt L, Hansmann M. Pregnancies following chronic intermittent (pulsatile) administration of GnRH by means of a portable pump (Zyklomat). A new approach to the treatment of infertility in hypothalamic amenorrhea J clin Endocrinol Metab 1980;51:1214-1216.
  92. Leyendecker G, Wildt L. Induction of ovulation with chronic-intermittent (pulsatile) administration of GnRH in hypothalamic amenorrhea. J Reprod Fertil 1983;69:397-409.
  93. Counseller VS. Endometriosis. A clinical and surgical review. Am J Obstet Gynecol 1938;36:877-886.
  94. Tseng JF, Ryan IP, Milam TD, Murai JT, Schriock ED, Landers DV, Taylor RN. Interleukin-6 secretion in vitro is up-regulated in ectopic and eutopic endometrial stromal cells from women with endometriosis. J Clin Endocrinol Metab 1996;81:1118-1122.
  95. Anaf V, Simon P, Fayt I, Noel JC. Smooth muscles are frequent components of endometriotic lesions. Hum Reprod 2000;15:767-771.
  96. Vercellini P, Aimi G, Panazza S, Vicentini S, Pisacreta A, Crosignani PG. Deep endometriosis conundrum: evidence in favor of a peritoneal origin. Fertil Steril 2000;73:1043-1046.
  97. Brosens IA, Brosens JJ. Redefining endometriosis: is deep endometriosis a progressive disease? Hum Reprod 2000;15:1-3.
  98. Kaiserman-Abramof IR u. Padykula HA. Ultrastructural epithelial zonation of the primate endometrium (rhesus monkey). Am J Anat 1989;184:13-30.
  99. Padykula HA, Coles LG, Okulicz WC, Rapaport SI, Mc Cracken JA, King NW jr, Longcope C, Kaiserman-Abramof IR. The basalis of the primate endometrium: A bifunctional germinal compartment. Biol Reprod 1989;40: 681-690.
  100. Okulicz WC, Balsamo M, Tast J. Progesterone regulation of endometrial estrogen receptor and cell proliferation during the late proliferative and secretory phase in artificial menstrual cycles in the rhesus monkey. Biol Reprod 1993;49:24-32.
  101. Delvoux B, Groothuis P, D'Hooghe T, Kyama C, Dunselman G, Romano A. Increased production of 17beta-estradiol in endometriosis lesions is the result of impaired metabolism J Clin Endocrinol Metab. 2009;94:876-883.
  102. McBean JH, Gibson M, Brumsted JR The association of intrauterine filling defects on hysterosalpingogram with endometriosis. Fertil Steril 1996;66:522-526.
  103. Bulun SE, Cheng YH, Yin P, Imir G, Utsunomiya H, Attar E, Innes J, Julie Kim J. Progesterone resistance in endometriosis: Link to failure to metabolize estradiol. Mol Cell Endocrinol 2006;248:94-103.
  104. Burney RO, Talbi S, Hamilton AE, Vo KC, Nyegaard M, Nezhat CR, Lessey BA, Giudice LC. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology 2007;148:3814-3826.
  105. Simon C, Gutierrez A, Vidal A, de los Santos MJ, Tarin JJ, Remohi J and Pellicer A. Outcome of patients with endometriosis in assisted reproduction: Results from in-vitro fertilization and oocyte donation. Hum Reprod 1994;9:725-729.
  106. Bulun SE, Cheng YH, Pavone ME, Yin P, Imir G, Utsunomiya H, Thung S, Xue Q, Marsh EE, Tokunaga H, Ishikawa H, Kurita T, Su EJ. 17Beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis. Semin Reprod Med 2010;28:44-50.
  107. Tsuno A, Nasu K, Yuge A, Matsumoto H, Nishida M, Narahara H. Decidualization attenuates the contractility of eutopic and ectopic endometrial stromal cells: implications for hormone therapy of endometriosis. J Clin Endocrinol Metab 2009;94:2516-2523.
  108. Zeitoun K, Takayama K, Sasano H, Suzuki HAT, Moghrabi N, Andersson S, Johns A, Meng L, Putman M, Carr B, Bulun SE. Deficient 17ß-hydroxysteroid dehydrogenase type 2 expression in endometriosis: Failure to metabolize 17ß-estradiol. J Clin Endocrinol Metab 1998;83:4474-4480.
  109. Anaf V, Simon P, El Nakadi I, Fayt I, Simonart T, Buxant F, Noel JC. Hyperalgesia, nerve infiltration and nerve growth factor expression in deep adenomyotic nodules, peritoneal and ovarian endometriosis. Hum Reprod 2002;17:1895-1900.
  110. Tokushige N, Markham R, Russell P, Fraser IS. Nerve fibres in peritoneal endometriosis. Hum Reprod 2006;21:3001-3007.
  111. Al-Jefout M, Dezarnaulds G, Cooper M, Tokushige N, Luscombe GM, Markham R, Fraser IS. Diagnosis of endometriosis by detection of nerve fibres in an endometrial biopsy: A double blind study. Hum Reprod. 2009;24:3019-3024.
  112. Bokor A, Kyama CM, Vercruysse L, Fassbender A, Gevaert O, Vodolazkaia A, De Moor B, Fülöp V, D'Hooghe T. Density of small diameter sensory nerve fibres in endometrium: A semi-invasive diagnostic test for minimal to mild endometriosis. Hum Reprod 2009;24:3025-3032.
  113. Mechsner S, Kaiser A, Kopf A, Gericke C, Ebert A, Bartley J. A pilot study to evaluate the clinical relevance of endometriosis-associated nerve fibers in peritoneal endometriotic lesions. Fertil Steril 2009;92:1856-1861.
  114. Zhang X, Lu B, Huang X, Xu H, Zhou C, Lin J. Innervation of endometrium and myometrium in women with painful adenomyosis and uterine fibroids. Fertil Steril 2010;94:730-737.
  115. Tokushige N, Markham R, Russell P, Fraser IS. Effect of progestogens and combined oral contraceptives on nerve fibers in peritoneal endometriosis. Fertil Steril 2009;92:1234-1239.
  116. Ackermann PW, Salo PT, Hart DA. Neuronal pathways in tendon healing. Front Biosci 2009;14:5165-5187.
  117. Salo PT, Beye JA, Seerattan RA, Leonard CA, Ivie TJ, Bray RC. Plasticity of peptidergic innervation in healing rabbit medial collateral ligament. Can J Surg 2008;51:167-172.
  118. Berkley KJ, Rapkin AJ, Papka RE. The pains of endometriosis. Science 2005; 308:1587-1589.
  119. Powell-Coffman JA, Bradfield CA, Wood WB. Caenorhabditis elegans orthologs of the aryl hydrocarbon receptor and its heterodimerization partner the aryl hydrocarbon receptor nuclear translocator. Proc Natl Acad Science USA 1998;95:2844-2849.
  120. Yasui T, Kim EY, Iwata H, Franks DG, Karchner SI, Hahn ME, Tanabe S. Functional characterization and evolutionary history of two aryl hydrocarbon receptor isoforms (AhR1 and AhR2) from avian species. Toxicol Science 2007;99:101-117.
  121. Küchenhoff A, Seliger G, Klonisch T, Tscheudschilsuren G, Kaltwasser P, Seliger E, Buchmann J, Fischer B. Arylhydrocarbon receptor expression in the human endometrium. Fertil Steril 1999;71:354-360.
  122. Hernández-Ochoa I, Karman BN, Flaws JA. The role of the aryl hydrocarbon receptor in the female reproductive system. Biochem Pharmacol 2009;77:547-559.
  123. DeCaterina R, Madonna R. Cytochromes CYP1A1 and CYP1B1: New pieces in the puzzle to understand the biomechanical paradigm of atherosclerosis. Cardiovasc Res 2009;81:629-632.
  124. Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol 2008;21:102-116.
  125. Nebert DW, Karp CL. Endogenous functions of the aryl hydrocarbon receptor (AHR): Intersection of cytochrome P450 1 (CYP1)-metabolized eicosanoids and AHR biology. J Biol Chem 2008;283:36061-36065.
  126. Khan S, Barhoumi R, Burghardt R, Liu S, Kim K, Safe S. Molecular mechanism of inhibitory aryl hydrocarbon receptor-estrogen receptor/Sp1 cross talk in breast cancer cells. Mol Endocrinol 2006;20:2199-2214.
  127. Bulun SE, Zeitoun KM, Kilic G. Expression of dioxin-related transactivating factors and target genes in human eutopic endometrial and endometriotic tissues. Am J Obstet Gynecol 2000;182:767-775.
  128. Kim SH, Choi YM, Lee GH, Hong MA, Lee KS, Lee BS, Kim JG, Moon SY. Association between susceptibility to advanced stage endometriosis and the genetic polymorphisms of aryl hydrocarbon receptor repressor and glutathione-S-transferase T1 genes. Hum Reprod. 2007;22:1866-1870.
  129. Singh MN, Stringfellow HF, Taylor SE, Ashton KM, Ahmad M, Abdo KR, El-Agnaf OM, Martin-Hirsch PL, Martin FL. Elevated expression of CYP1A1 and gamma-SYNUCLEIN in human ectopic (ovarian) endometriosis compared with eutopic endometrium. Mol Hum Reprod 2008;14:655-663.
  130. Guo SW, Simsa P, Kyama CM, Mihályi A, Fülöp V, Othman EE, D'Hooghe TM. Reassessing the evidence for the link between dioxin and endometriosis: from molecular biology to clinical epidemiology. Mol Hum Reprod 2009;15:609-624.
  131. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Science USA 1996;93:10417-10422.
  132. Conway DE, Sakurai Y, Weiss D, Vega JD, Taylor WR, Jo H, Eskin SG, Marcus CB, McIntire LV. Expression of CYP1A1 and CYP1B1 in human endothelial cells: Regulation by fluid shear stress. Cardiovasc Res. 2009;81:669-677.
  133. Rickes D, Nickel I, Kropf S, Kleinstein J. Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertil Steril 2002;78:757-762.
  134. Meyer RM, Barton M. ER?, ERß, and gpER: Novel aspects of oestrogen receptor signalling in atherosclerosis. Cardiovasc Res 2009;83:605-610.

Blutungsstörungen (Teil 3): Endokrine Ursachen bei Durchbruchblutungen

Gemeinsame Stellungnahme der DGGEF e.V. und des BVF e.V. (Prof. Dr. med. Dr. med. h.c. Thomas Rabe federführend) und des Arbeitskreises „Blutungsstörungen bei der Frau“
Seiten 38-45

 

  1. Pratt WF, Bachrach CA. What do women use when they stop using the pill? Fam Plann Perspect 1987;19:257–266.
  2. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577–582.
  3. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 2006 Sep;74(3):220-223.
  4. Pratt WF, Bachrach CA. What do women use when they stop using the pill? Fam Plann Perspect 1987;19:257–266.
  5. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577–582.
  6. Speroff L, Darney PD. A Clinical Guide for Contraception. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001.
  7. Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: A prospective evaluation. Fam Plann Perspect 1998;30:89–104.
  8. Hatcher RA, Trussell J, Stewart FH. Contraceptive Technology. 18th ed. New York: Ardent Media; 2004.
  9. Thorneycroft IH. Cycle control with oral contraceptives: A review of the literature. Am J Obstet Gynecol 1999;180:280–287.
  10. Lohr PA, Creinin MD. Oral contraceptives and breakthrough bleeding. What patients need to know. J Family Practice 2006;55:No.10,1-11.
  11. Middleton LJ, Champaneria R, Daniels JP, Bhattacharya S, Cooper KG, Hilken NH et al. Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: Systematic review and meta-analysis of data from individual patients. BMJ 2010;341:c3929.
  12. ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod 2001;16:1527–1535.
  13. Astedt B, Jeppsson S, Liedholm P, Rannevik G, Svanberg L. Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17 betaoestradiol. Br J Obstet Gynaecol 1979; 86:732–736.
  14. Csemiczky G, Dieben T, Coeling Bennink HJ, Landgren BM. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0,150 mg desogestrel for 21 days, followed by 0,030 mg desogestrel only for 7 days. Contraception 1996; 54:333–338.
  15. Hirvonen E, Allonen H, Anttila M et al. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas 1995; 21:27–33.
  16. Kivinen S, Saure A. Efficacy and tolerability of a combined oral contraceptive containing 17 betaestradiol and desogestrel. EUR J Contracept Reprod Health Care 1996; 1:183.
  17. Koetsawang S, Mandlekar AV, Krishna UR et al. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. World Health Organisation Task Force on Oral Contraception. Contraception 1980;21:445–459.
  18. Schubert W, Cullberg G. Ovulation inhibition with 17 beta-estradiol cyclo-octyl acetate and desogestrel. Acta Obstet Gynecol Scand 1987;66:543–547.
  19. Serup J, Bostofte E, Larsen S, Westergaard J, Lebech PE. Natural oestrogens for oral contraception. Lancet 1979;2:471–472.
  20. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol. Fertil Steril 1993;60:616–619.
  21. Astedt et al. Br J Obstet Gynaecol 1979;86:732–736.
  22. Kivinen S, Saure A. Efficacy and tolerability of a combined oral contraceptive containing 17 beta-estradiol and desogestrel. Eur J Contracept Reprod Health Care 1996;1:183.
  23. Koetsawang S, Mandlekar AV, Krishna UR et al. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. World Health Organisation. Task Force on Oral Contraception. Contraception 1980;21:445–459.
  24. Schubert W, Cullberg G. Ovulation inhibition with 17 beta-estradiol cyclo-octyl acetate and desogestrel. Acta Obstet Gynecol Scand 1987;66:543–547.
  25. Serup J, Bostofte E, Larsen S, Westergaard J, Lebech PE. Natural oestrogens for oral contraception. Lancet 1979;2:471–472.
  26. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol. Fertil Steril 1993;60:616–619.
  27. Mueck AO, Seeger H, Bühling KJ. Why use of dienogest for the first contraceptive pill with estradiol? Gynecological endocrinology: The official journal of the International Society of Gynecological Endocrinology 2010;26(2):109-113.
  28. Ahrendt H-J, Makalová D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: A seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinylestradiol/levonorgestrel. Contraception 2009;80:436–444.
  29. Kaunitz AM. Oral contraceptive estrogen dose considerations. Contraception 1998;58(Suppl):15S–21S.
  30. Preston SN. A report of a collaborative dose-response clinical study using decreasing doses of combination oral contraceptives. Contraception 1972;6:17–35.
  31. Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinylestradiol. Br J Obstet Gynaecol 1993;100:832.
  32. Endrikat J, Cronin M, Gerlinger C, Rübig A, Schmidt W, Düsterberg B. Open, multicenter comparison of efficacy, cycle control and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinylestradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinylestradiol and 150 microg desogestrel. Contraception 2001 Sep;64(3):201-207.
  33. Gallo MF, Nanda K, Grimes DA, Schulz KF. Twenty micrograms versus > 20 microg estrogen oral contraceptives for contraception: A systematic review of randomized controlled trials. Contraception 2005;71:162–169.
  34. Endrikat J, Hite R, Bannemerschult R, Gerlinger C, Schmidt W. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/50 microg noresthisterone. Contraception 2001;64:3–10.
  35. Saleh WA, Burkman RT, Zacur HA, Kimball AW, Kwieterovich P, Bell W. A randomized trial of three oral contraceptives: Comparison of bleeding patterns by contraceptive types and steroid levels. Am J Obstet Gynecol 1993;168:1740–1747.
  36. Stenchever MA, Ling FW. Comprehensive Gynecology. 4th ed. St Louis; Mo Mosby 2001.
  37. Maitra N, Kulier R, Bloemenkamp KW, Helmerhorst FM, Gulmezoglu AM. Progestogens in combined oral contraceptives for contraception. Cochrane Database Syst Rev 2004;(3):CD004861.
  38. Lawson JS, Yuliano SE, Pasquale SA, Osterman JJ. Optimum dosing of an oral contraceptive. A report from the study of seven combinations of norgestimate and ethinyl estradiol. Am J Obstet Gynecol 1979;134:315–320.
  39. Upton GV. The phasic approach to oral contraception: The triphasic concept and its clinical application. Int J Fertil Steril 1983;28:121–140.
  40. Mishell DR Jr. Oral contraception: Past, present and future perspectives. Int J Fertil Steril 1991;37(Suppl):7–18.
  41. Van Vliet H, Grimes D, Helmerhorst F, Schulz K. Biphasic versus triphasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006;3:CD003283.
  42. Van Vliet H, Grimes D, Helmerhorst F, Schulz K. Biphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006;3:CD002032.
  43. Van Vliet H, Grimes DA, Helmerhorst FM, Schulz KF, Lopez LM. Biphasic versus monophasic oral contraceptives for contraception. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD002032. DOI: 10.1002/14651858.CD002032.pub2.
  44. Van Vliet H, Grimes DA, Helmerhorst FM, Schulz KF, Lopez LM. Biphasic versus triphasic oral contraceptives for contraception. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD003283. DOI: 10.1002/14651858.CD003283.pub2
  45. Van Vliet H, Marjolein Raps, Laureen M Lopez, Frans M Helmerhorst. Quadriphasic versus monophasic oral contraceptives for contraception. Cochrane Fertility Regulation Group, Published Online: 16 MAR 2011, DOI: 10.1002/14651858.CD009038.
  46. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89–96.
  47. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinylestradiol: Phase 3 study results. Contraception 2006;74(6):439–445.
  48. Corson SL. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. US clinical trials. Acta Obstet Gynecol Scand Suppl 1990;152:25–31.
  49. Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling, and satisfaction with oral contraceptives: A prospective evaluation. Fam Plann Perspect 1998;30:89–104.
  50. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation. Contraception 1995;51:283– 288.
  51. Potter L, Oakley D, de Leon-Wong E, Canamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996;28:154–158.
  52. Stubblefield PG. Menstrual impact of contraception. Am J Obstet Gynecol 1994;170:1513–1522.
  53. Talwar PP, Dingfelder JR, Ravenholt RT. Increased risk of breakthrough bleeding when one oral-contraceptive tablet is missed. N Engl J Med 1977;296:1236–1237.
  54. Wallach M, Grimes DA. Modern Oral Contraception: Updates from the Contraceptive Report. Totowa, NJ: Emron; 2000.
  55. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John’s Wort with oral contraceptives: Effects on the pharmacokinectics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005;71:402– 408.
  56. Sparrow MJ. Pregnancies in reliable pill takers. NZ Med J 1989;102:575–577.
  57. Kanarkowski R, Tornatore KM, D’Ambrosio R, Gardner MJ, Jusko WJ. Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Clin Pharmacol Ther 1988;43:23–31.
  58. Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol 1996;174:628–632.
  59. Vessey MP, Villard-Makintosh L, Jacobs HS. Antiestrogenic effect of cigarette smoking. N Engl J Med 1987;317:769–770.
  60. Faculty of Family Planning and Reproductive Health Care. Clinical Effectiveness Unit. FFPRHC Guidance: First prescription of combined oral contraception. J Fam Plann Reprod Health Care 2003;29:209–222.
  61. Krettek JE, Arkin SI, Chaisilwattana P, Monif GR. Chlamydia trachomatis in patients who used oral contraceptives and had intermenstrual spotting. Obstet Gynecol. 1993;81(5):728-731.
  62. Morrison CS, Bright P, Wong EL, Kwok C, Yacobson I, Gaydos CA, Tucker HT, Blumenthal PD. Hormonal contraceptive use, cervical ectopy and the acquisition of cervical infections. Sex Transm Dis. 2004 Sep;31(9):561-567.
  63. Mears E, Grant ECG. Anovlar as an oral contraceptive. British medical Journal 1962;7:75-79.
  64. Pincus G, Rock J and Garcia CR. Proceedings of International Conference on Planned Parenthood; New Delhi 1959:216. International Planned Parenthood Association, London.
  65. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 ?g versus >20 ?g estrogen combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD003989. DOI: 10.1002/14651858.CD003989.pub4.
  66. Ahrendt H-J, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: A 7-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinylestradiol/levonorgestrel. Contraception 2009 Nov;80(5):436-444.
  67. Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinylestradiol. Br J  Obstet Gynaecol 1993;100:832-838.
  68. Rice C, Killick S, Hickling D, Coelingh BH. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod 1996;11:737–740.
  69. Collaborative Study Group on the Desogestrel-Containing Progestogen-Only Pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogenonly pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Eur J Contracept Reprod Health Care 1998;3:169–178.
  70. BZgA. Verhütungsverhalten Erwachsener; Ergebnisse der Repräsentativbefragung 2007.
  71. Hammerstein J. Komplikationen und Spätfolgen der Kontrazeption, einschließlich der Sterilisation. Arch. Gynaekol 1977;224:1-21